Targeted drug therapy in nonsmall cell lung cancer: clinical significance and possible solutions-part II (role of nanocarriers)
Nonsmall cell lung cancer (NSCLC) accounts for 80-85% of the cases of lung cancer. The conventional therapeutic effective dosage forms used to treat NSCLC are associated with rigid administration schedules, adverse effects, and may be associated with acquired resistance to therapy. Nanocarriers may...
Uložené v:
| Vydané v: | Expert opinion on drug delivery Ročník 18; číslo 1; s. 103 - 118 |
|---|---|
| Hlavní autori: | , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
England
Taylor & Francis
02.01.2021
|
| Predmet: | |
| ISSN: | 1742-5247, 1744-7593, 1744-7593 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Nonsmall cell lung cancer (NSCLC) accounts for 80-85% of the cases of lung cancer. The conventional therapeutic effective dosage forms used to treat NSCLC are associated with rigid administration schedules, adverse effects, and may be associated with acquired resistance to therapy. Nanocarriers may provide a suitable alternative to regular formulations to overcome inherent drawbacks and provide better treatment modalities for the patient.
The article explores the application of drug loaded nanocarriers for lung cancer treatment. Drug-loaded nanocarriers can be modified to achieve controlled delivery at the desired tumor infested site. The type of nanocarriers employed are diverse based on polymers, liposomes, metals and a combination of two or more different base materials (hybrids). These may be designed for systemic delivery or local delivery to the lung compartment (via inhalation).
Nanocarriers can improve pharmacokinetics of the drug payload by improving its delivery to the desired location and can reduce associated systemic toxicities. Through nanocarriers, a wide variety of therapeutics can be administered and targeted to the cancerous site. Some examples of the utilities of nanocarriers are codelivery of drugs, gene delivery, and delivery of other biologics. Overall, the nanocarriers have promising potential in improving therapeutic efficacy of drugs used in NSCLC. |
|---|---|
| AbstractList | Nonsmall cell lung cancer (NSCLC) accounts for 80-85% of the cases of lung cancer. The conventional therapeutic effective dosage forms used to treat NSCLC are associated with rigid administration schedules, adverse effects, and may be associated with acquired resistance to therapy. Nanocarriers may provide a suitable alternative to regular formulations to overcome inherent drawbacks and provide better treatment modalities for the patient.
The article explores the application of drug loaded nanocarriers for lung cancer treatment. Drug-loaded nanocarriers can be modified to achieve controlled delivery at the desired tumor infested site. The type of nanocarriers employed are diverse based on polymers, liposomes, metals and a combination of two or more different base materials (hybrids). These may be designed for systemic delivery or local delivery to the lung compartment (via inhalation).
Nanocarriers can improve pharmacokinetics of the drug payload by improving its delivery to the desired location and can reduce associated systemic toxicities. Through nanocarriers, a wide variety of therapeutics can be administered and targeted to the cancerous site. Some examples of the utilities of nanocarriers are codelivery of drugs, gene delivery, and delivery of other biologics. Overall, the nanocarriers have promising potential in improving therapeutic efficacy of drugs used in NSCLC. Nonsmall cell lung cancer (NSCLC) accounts for 80-85% of the cases of lung cancer. The conventional therapeutic effective dosage forms used to treat NSCLC are associated with rigid administration schedules, adverse effects, and may be associated with acquired resistance to therapy. Nanocarriers may provide a suitable alternative to regular formulations to overcome inherent drawbacks and provide better treatment modalities for the patient.INTRODUCTIONNonsmall cell lung cancer (NSCLC) accounts for 80-85% of the cases of lung cancer. The conventional therapeutic effective dosage forms used to treat NSCLC are associated with rigid administration schedules, adverse effects, and may be associated with acquired resistance to therapy. Nanocarriers may provide a suitable alternative to regular formulations to overcome inherent drawbacks and provide better treatment modalities for the patient.The article explores the application of drug loaded nanocarriers for lung cancer treatment. Drug-loaded nanocarriers can be modified to achieve controlled delivery at the desired tumor infested site. The type of nanocarriers employed are diverse based on polymers, liposomes, metals and a combination of two or more different base materials (hybrids). These may be designed for systemic delivery or local delivery to the lung compartment (via inhalation).AREAS COVEREDThe article explores the application of drug loaded nanocarriers for lung cancer treatment. Drug-loaded nanocarriers can be modified to achieve controlled delivery at the desired tumor infested site. The type of nanocarriers employed are diverse based on polymers, liposomes, metals and a combination of two or more different base materials (hybrids). These may be designed for systemic delivery or local delivery to the lung compartment (via inhalation).Nanocarriers can improve pharmacokinetics of the drug payload by improving its delivery to the desired location and can reduce associated systemic toxicities. Through nanocarriers, a wide variety of therapeutics can be administered and targeted to the cancerous site. Some examples of the utilities of nanocarriers are codelivery of drugs, gene delivery, and delivery of other biologics. Overall, the nanocarriers have promising potential in improving therapeutic efficacy of drugs used in NSCLC.EXPERT OPINIONNanocarriers can improve pharmacokinetics of the drug payload by improving its delivery to the desired location and can reduce associated systemic toxicities. Through nanocarriers, a wide variety of therapeutics can be administered and targeted to the cancerous site. Some examples of the utilities of nanocarriers are codelivery of drugs, gene delivery, and delivery of other biologics. Overall, the nanocarriers have promising potential in improving therapeutic efficacy of drugs used in NSCLC. |
| Author | Misra, Ambikanandan Upadhya, Archana Yadav, Khushwant S. |
| Author_xml | – sequence: 1 givenname: Khushwant S. surname: Yadav fullname: Yadav, Khushwant S. organization: Svkm's Nmims – sequence: 2 givenname: Archana surname: Upadhya fullname: Upadhya, Archana organization: Svkm's Nmims – sequence: 3 givenname: Ambikanandan surname: Misra fullname: Misra, Ambikanandan email: misraan@hotmail.com, ambikanandan.misra@nmims.edu organization: Svkm's Nmims |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33017541$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkUtv1DAUhS1URB_wE0BelkUG27GTDGxAFY-RKrEpa-vGvhmMHDvYiapZ8ddxOlMWLGBjW0ffOda955KchRiQkJecbTjr2BveSqGEbDeCCb7hXS223fYJuSi6rFq1rc8e3qJaoXNymfMPxuqmZfwZOa9rxlsl-QX5dQdpjzNaatOyp_N3TDAdqAu0_JdH8J4aLIdfwp4aCAbTW2q8C86Ap9ntgxvcg04hWDrFnF3vkebol9mViGqCNNPdjl6nWPQ40AAhGkjJYcqvn5OnA_iML073Ffn26ePdzZfq9uvn3c2H28rUTTNXTY_SsK1UnZCNRYWSSybAQM_7RrXMMma54lZww5VFaQGhtXzgMCAq1dZX5PqYO6X4c8E869HldTIIGJeshZRdJxvOmoK-OqFLP6LVU3IjpIN-XFoB1BEwqYybcPiDcKbXcvRjOXotR5_KKb53f_mMm2Hd0pzA-f-63x_dLgwxjXAfk7d6hoOPaUilAZd1_e-I39y7qQE |
| CitedBy_id | crossref_primary_10_1007_s12032_025_02680_x crossref_primary_10_1016_j_jddst_2023_105210 crossref_primary_10_1002_ardp_70013 crossref_primary_10_1002_slct_202402903 crossref_primary_10_1002_mco2_618 crossref_primary_10_1007_s13205_022_03365_2 crossref_primary_10_3389_fphar_2023_1242488 crossref_primary_10_3390_pharmaceutics13122120 crossref_primary_10_1016_j_drudis_2023_103701 crossref_primary_10_3390_pharmaceutics15010139 crossref_primary_10_1080_07357907_2025_2559088 crossref_primary_10_25259_ASJO_19_2023 crossref_primary_10_1016_j_jconrel_2021_07_003 crossref_primary_10_1007_s12668_025_02132_w crossref_primary_10_1038_s41598_022_08759_z |
| Cites_doi | 10.1016/j.jconrel.2016.11.005 10.1016/j.biopha.2018.05.095 10.2147/DDDT.S143047 10.1016/j.tibtech.2017.12.001 10.1080/17435390701675914 10.3390/ijms20215243 10.1039/C6BM00449K 10.31557/APJCP.2019.20.7.2225 10.1016/j.addr.2010.03.011 10.1016/j.lfs.2019.117060 10.1016/j.ejps.2015.10.021 10.1016/j.nantod.2019.03.007 10.1016/j.drudis.2006.07.005 10.1016/j.nano.2016.02.007 10.1080/21691401.2019.1615932 10.1016/j.ajps.2018.09.009 10.3109/02652048.2011.615949 10.1016/j.jconrel.2016.06.012 10.1016/j.jconrel.2017.11.036 10.1016/j.ajps.2015.08.009 10.1007/s13346-018-0509-5 10.1016/j.biomaterials.2019.119299 10.1177/1758834015584763 10.1186/2228-5326-2-32 10.1016/S0927-7765(02)00042-5 10.1002/btm2.10003 10.1101/cshperspect.a028241 10.1016/j.jcis.2016.07.006 10.1186/s12989-014-0046-4 10.1080/17425247.2019.1614911 10.7150/thno.39816 10.1016/j.drudis.2019.09.023 10.1038/cgt.2012.26 10.1002/ddr.21698 10.1016/B978-0-08-046884-6.00104-4 10.1016/j.ijpharm.2011.09.006 10.1016/j.ctarc.2019.100157 10.1016/j.arabjc.2018.04.013 10.1080/10717544.2018.1425777 10.1016/j.jconrel.2011.08.017 10.1016/j.addr.2006.09.009 10.3390/pharmaceutics12030206 10.1016/j.cis.2017.01.007 10.1021/acs.molpharmaceut.7b00900 10.1007/s002800000230 10.1002/smll.201303635 10.1039/C7SC04004K 10.1016/j.pupt.2019.02.001 10.1080/03639045.2017.1310223 10.3109/1061186X.2014.979829 10.1021/acsami.9b02986 10.1021/acsbiomaterials.9b01639 10.1016/j.jconrel.2015.10.055 10.1016/j.jconrel.2010.10.035 10.1016/j.jconrel.2011.02.029 10.3390/cancers3010106 10.2147/IJN.S129274 10.1021/mp300152v 10.1080/02652048.2018.1453560 10.1039/C9TB02055A 10.1016/j.cllc.2015.05.004 10.1038/srep39805 10.3390/molecules24061035 10.1111/cas.14256 10.3390/nano9071052 10.1080/1061186X.2017.1419360 10.3109/10731199.2011.592494 10.1016/j.nano.2011.12.007 10.1016/j.biopha.2019.109561 10.1016/S0167-4781(99)00153-0 10.3389/fphar.2018.01214 10.1016/j.jsps.2014.04.001 10.1016/j.bfopcu.2017.06.003 10.1038/s41467-018-03705-y 10.1038/aps.2017.34 10.1186/s12860-017-0140-1 10.1016/j.drudis.2014.09.020 10.1021/acsami.0c01069 10.1038/srep07085 10.3892/ol.2014.2840 10.3109/02652048.2014.940011 10.3390/nano1010031 10.1016/j.canlet.2018.01.024 10.1016/j.jddst.2020.101684 10.1021/bc2005522 10.2147/IJN.S174909 10.1038/s41416-020-0765-2 10.1088/1361-6528/aa9a19 10.1016/j.ijpharm.2017.05.016 10.1039/C5TB00912J 10.1016/j.jconrel.2014.06.038 10.1080/10717544.2018.1477856 10.2147/IJN.S110488 10.1097/JTO.0b013e3181d5e39e 10.1016/j.ejpb.2018.06.027 10.1007/s11095-020-02790-3 10.2147/IJN.S140957 10.1080/14656566.2018.1546290 10.1038/s41598-018-31332-6 10.1016/B978-0-12-817909-3.00007-8 10.4018/978-1-5225-4781-5.ch007 10.1089/bioe.2020.0012 10.2147/IJN.S46900 10.1016/j.jcis.2016.07.020 10.1080/21691401.2018.1559176 10.1016/j.drudis.2020.06.027 10.1166/jbn.2007.015 10.1200/JCO.2007.15.0375 10.1016/j.ijpharm.2010.12.040 10.1007/978-3-319-50688-3_21 10.1080/21691401.2019.1645152 10.3389/fphar.2020.00898 10.1016/j.jddst.2019.101316 10.3390/nano10020183 10.1186/1477-3155-11-1 10.2174/1381612826666200318170716 10.1016/j.jddst.2020.101502 10.1016/j.biomaterials.2013.03.061 10.1016/j.ejps.2017.03.025 10.1016/j.biomaterials.2013.01.063 10.1186/s12951-014-0037-5 10.2147/IJN.S30320 10.1517/17425240902939143 10.1016/j.biomaterials.2015.08.048 10.1158/0008-5472.CAN-15-1558 10.1016/j.actbio.2018.03.057 10.1016/j.biomaterials.2013.05.018 10.1080/10717544.2019.1642420 10.2217/17435889.3.1.1 10.1289/ehp.84553 10.1016/j.jconrel.2018.12.002 10.1517/17425240802652309 10.1080/08958370601051677 10.2147/IJN.S121881 10.29245/2689-999X/2019/2.1148 |
| ContentType | Journal Article |
| Copyright | 2020 Informa UK Limited, trading as Taylor & Francis Group 2020 |
| Copyright_xml | – notice: 2020 Informa UK Limited, trading as Taylor & Francis Group 2020 |
| DBID | AAYXX CITATION NPM 7X8 |
| DOI | 10.1080/17425247.2021.1832989 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1744-7593 |
| EndPage | 118 |
| ExternalDocumentID | 33017541 10_1080_17425247_2021_1832989 1832989 |
| Genre | Review Journal Article |
| GroupedDBID | --- 00X 03L 0R~ 29G 4.4 53G 5GY AAMIU AAOUU ABEIZ ABJNI ABLIJ ABLKL ABXYU ACGFS ACIEZ ADCVX ADRBQ AECIN AENEX AEOZL AFRVT AGDLA AGMLL AIJEM AIRBT AIYSM AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU AQTUD BABNJ BLEHA CCCUG CS3 DKSSO DU5 EBS F5P H13 HZ~ KRBQP KSSTO KWAYT KYCEM LJTGL M4Z O9- P2P RNANH TASJS TBQAZ TDBHL TERGH TFDNU TFL TFW TUROJ TZHSB V1S ~1N AAYXX CITATION 0BK AAPWH ABBAB ABJYH ABVAX ADTOD CAZVN DASJU DAWQK EJD M44 NPM 7X8 |
| ID | FETCH-LOGICAL-c366t-6be4c09458246de5e41402acab1b6570d00d151d21c15de4daea7d1f1afee5573 |
| IEDL.DBID | TFW |
| ISICitedReferencesCount | 17 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000577292400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1742-5247 1744-7593 |
| IngestDate | Thu Sep 04 16:24:36 EDT 2025 Thu Jan 02 22:57:37 EST 2025 Tue Nov 18 22:19:01 EST 2025 Sat Nov 29 06:32:43 EST 2025 Mon Oct 20 23:48:39 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | gene delivery cell line studies animal studies clinical trials NSCLC Nanocarriers |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c366t-6be4c09458246de5e41402acab1b6570d00d151d21c15de4daea7d1f1afee5573 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 33017541 |
| PQID | 2448846106 |
| PQPubID | 23479 |
| PageCount | 16 |
| ParticipantIDs | informaworld_taylorfrancis_310_1080_17425247_2021_1832989 pubmed_primary_33017541 crossref_citationtrail_10_1080_17425247_2021_1832989 proquest_miscellaneous_2448846106 crossref_primary_10_1080_17425247_2021_1832989 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-01-02 |
| PublicationDateYYYYMMDD | 2021-01-02 |
| PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-02 day: 02 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Expert opinion on drug delivery |
| PublicationTitleAlternate | Expert Opin Drug Deliv |
| PublicationYear | 2021 |
| Publisher | Taylor & Francis |
| Publisher_xml | – name: Taylor & Francis |
| References | cit0077 cit0110 cit0078 cit0111 cit0075 cit0076 cit0073 cit0074 cit0071 cit0072 cit0070 cit0118 cit0119 cit0116 cit0117 cit0114 cit0115 cit0079 cit0112 cit0066 cit0100 cit0064 cit0065 cit0062 cit0063 cit0060 cit0061 cit0109 cit0107 cit0108 cit0105 cit0106 cit0103 cit0104 cit0068 cit0101 cit0069 cit0102 cit0011 cit0099 cit0132 cit0012 cit0133 cit0097 cit0130 cit0010 cit0098 cit0131 cit0095 cit0096 cit0093 cit0094 cit0091 cit0092 Zarogoulidis K (cit0090) 2013; 5 cit0019 cit0017 cit0138 cit0018 cit0139 cit0015 cit0136 cit0016 cit0137 cit0013 cit0134 cit0014 cit0135 cit0088 cit0121 cit0001 cit0089 cit0122 cit0086 cit0087 Chen Y (cit0113) cit0084 cit0085 cit0082 cit0083 cit0080 cit0081 cit0008 cit0129 cit0009 cit0006 cit0127 cit0007 cit0128 cit0004 cit0125 cit0005 cit0126 cit0002 cit0123 cit0003 cit0124 cit0033 cit0031 cit0032 cit0030 cit0039 Honary S (cit0067) 2013; 12 cit0037 cit0038 cit0035 cit0036 cit0022 cit0143 cit0023 cit0144 cit0020 cit0141 cit0021 cit0142 cit0140 Nan Y (cit0120) 2019; 42 cit0028 cit0029 cit0026 cit0027 cit0024 cit0145 cit0025 cit0146 cit0056 cit0053 cit0054 cit0051 cit0052 cit0050 Wang W (cit0034) 2015; 10 Qian Y (cit0055) 2014; 4 cit0059 cit0057 cit0058 cit0044 cit0045 cit0042 cit0043 cit0040 cit0041 cit0048 cit0049 cit0046 cit0047 |
| References_xml | – ident: cit0069 doi: 10.1016/j.jconrel.2016.11.005 – ident: cit0043 doi: 10.1016/j.biopha.2018.05.095 – ident: cit0064 doi: 10.2147/DDDT.S143047 – ident: cit0136 doi: 10.1016/j.tibtech.2017.12.001 – ident: cit0113 publication-title: Acta Pharm Sin B – ident: cit0023 doi: 10.1080/17435390701675914 – ident: cit0009 doi: 10.3390/ijms20215243 – ident: cit0091 doi: 10.1039/C6BM00449K – ident: cit0005 doi: 10.31557/APJCP.2019.20.7.2225 – ident: cit0036 doi: 10.1016/j.addr.2010.03.011 – ident: cit0012 doi: 10.1016/j.lfs.2019.117060 – ident: cit0129 doi: 10.1016/j.ejps.2015.10.021 – ident: cit0014 doi: 10.1016/j.nantod.2019.03.007 – ident: cit0037 doi: 10.1016/j.drudis.2006.07.005 – ident: cit0108 doi: 10.1016/j.nano.2016.02.007 – ident: cit0042 doi: 10.1080/21691401.2019.1615932 – ident: cit0101 doi: 10.1016/j.ajps.2018.09.009 – ident: cit0128 doi: 10.3109/02652048.2011.615949 – ident: cit0075 doi: 10.1016/j.jconrel.2016.06.012 – ident: cit0098 doi: 10.1016/j.jconrel.2017.11.036 – ident: cit0097 doi: 10.1016/j.ajps.2015.08.009 – ident: cit0112 doi: 10.1007/s13346-018-0509-5 – ident: cit0033 doi: 10.1016/j.biomaterials.2019.119299 – ident: cit0094 doi: 10.1177/1758834015584763 – ident: cit0024 doi: 10.1186/2228-5326-2-32 – ident: cit0144 – ident: cit0086 doi: 10.1016/S0927-7765(02)00042-5 – ident: cit0138 doi: 10.1002/btm2.10003 – ident: cit0084 doi: 10.1101/cshperspect.a028241 – ident: cit0087 doi: 10.1016/j.jcis.2016.07.006 – ident: cit0050 doi: 10.1186/s12989-014-0046-4 – ident: cit0017 doi: 10.1080/17425247.2019.1614911 – ident: cit0019 doi: 10.7150/thno.39816 – ident: cit0079 doi: 10.1016/j.drudis.2019.09.023 – ident: cit0007 doi: 10.1038/cgt.2012.26 – ident: cit0025 doi: 10.1002/ddr.21698 – ident: cit0077 doi: 10.1016/B978-0-08-046884-6.00104-4 – ident: cit0035 doi: 10.1016/j.ijpharm.2011.09.006 – ident: cit0058 doi: 10.1016/j.ctarc.2019.100157 – ident: cit0145 – ident: cit0047 doi: 10.1016/j.arabjc.2018.04.013 – ident: cit0040 doi: 10.1080/10717544.2018.1425777 – ident: cit0020 doi: 10.1016/j.jconrel.2011.08.017 – ident: cit0010 doi: 10.1016/j.addr.2006.09.009 – ident: cit0132 doi: 10.3390/pharmaceutics12030206 – ident: cit0053 doi: 10.1016/j.cis.2017.01.007 – ident: cit0088 doi: 10.1021/acs.molpharmaceut.7b00900 – ident: cit0102 doi: 10.1007/s002800000230 – ident: cit0022 doi: 10.1002/smll.201303635 – ident: cit0092 doi: 10.1039/C7SC04004K – ident: cit0116 doi: 10.1016/j.pupt.2019.02.001 – ident: cit0110 doi: 10.1080/03639045.2017.1310223 – ident: cit0039 doi: 10.3109/1061186X.2014.979829 – ident: cit0057 doi: 10.1021/acsami.9b02986 – ident: cit0119 doi: 10.1021/acsbiomaterials.9b01639 – ident: cit0008 doi: 10.1016/j.jconrel.2015.10.055 – ident: cit0106 doi: 10.1016/j.jconrel.2010.10.035 – ident: cit0013 doi: 10.1016/j.jconrel.2011.02.029 – ident: cit0031 doi: 10.3390/cancers3010106 – ident: cit0056 doi: 10.2147/IJN.S129274 – ident: cit0126 doi: 10.1021/mp300152v – ident: cit0142 – ident: cit0015 doi: 10.1080/02652048.2018.1453560 – ident: cit0071 doi: 10.1039/C9TB02055A – volume: 10 start-page: 3737 year: 2015 ident: cit0034 publication-title: Int J Nanomedicine – ident: cit0140 doi: 10.1016/j.cllc.2015.05.004 – ident: cit0060 doi: 10.1038/srep39805 – ident: cit0061 doi: 10.3390/molecules24061035 – ident: cit0041 doi: 10.1111/cas.14256 – ident: cit0089 doi: 10.3390/nano9071052 – ident: cit0123 doi: 10.1080/1061186X.2017.1419360 – ident: cit0096 doi: 10.3109/10731199.2011.592494 – ident: cit0104 doi: 10.1016/j.nano.2011.12.007 – ident: cit0045 doi: 10.1016/j.biopha.2019.109561 – ident: cit0099 doi: 10.1016/S0167-4781(99)00153-0 – ident: cit0127 doi: 10.3389/fphar.2018.01214 – ident: cit0018 doi: 10.1016/j.jsps.2014.04.001 – ident: cit0143 – volume: 42 start-page: 2087 issue: 5 year: 2019 ident: cit0120 publication-title: Oncol Rep – ident: cit0065 doi: 10.1016/j.bfopcu.2017.06.003 – ident: cit0137 doi: 10.1038/s41467-018-03705-y – ident: cit0095 doi: 10.1038/aps.2017.34 – ident: cit0048 doi: 10.1186/s12860-017-0140-1 – ident: cit0082 doi: 10.1016/j.drudis.2014.09.020 – ident: cit0118 doi: 10.1021/acsami.0c01069 – ident: cit0111 doi: 10.1038/srep07085 – ident: cit0114 doi: 10.3892/ol.2014.2840 – ident: cit0131 doi: 10.3109/02652048.2014.940011 – ident: cit0054 doi: 10.3390/nano1010031 – ident: cit0070 doi: 10.1016/j.canlet.2018.01.024 – ident: cit0133 doi: 10.1016/j.jddst.2020.101684 – ident: cit0093 doi: 10.1021/bc2005522 – ident: cit0026 doi: 10.2147/IJN.S174909 – ident: cit0117 doi: 10.1038/s41416-020-0765-2 – ident: cit0072 doi: 10.1088/1361-6528/aa9a19 – ident: cit0004 doi: 10.1016/j.ijpharm.2017.05.016 – ident: cit0124 doi: 10.1039/C5TB00912J – ident: cit0066 doi: 10.1016/j.jconrel.2014.06.038 – ident: cit0130 doi: 10.1080/10717544.2018.1477856 – ident: cit0044 doi: 10.2147/IJN.S110488 – volume: 4 start-page: 1 issue: 1 year: 2014 ident: cit0055 publication-title: Sci Rep – ident: cit0141 doi: 10.1097/JTO.0b013e3181d5e39e – ident: cit0109 doi: 10.1016/j.ejpb.2018.06.027 – ident: cit0107 doi: 10.1007/s11095-020-02790-3 – ident: cit0073 doi: 10.2147/IJN.S140957 – volume: 5 start-page: 2 issue: 4 year: 2013 ident: cit0090 publication-title: J Thorac Dis – ident: cit0139 doi: 10.1080/14656566.2018.1546290 – ident: cit0134 doi: 10.1038/s41598-018-31332-6 – ident: cit0032 doi: 10.1016/B978-0-12-817909-3.00007-8 – ident: cit0049 doi: 10.4018/978-1-5225-4781-5.ch007 – ident: cit0068 doi: 10.1089/bioe.2020.0012 – volume: 12 start-page: 255 issue: 2 year: 2013 ident: cit0067 publication-title: Trop J Pharm Res – ident: cit0003 doi: 10.2147/IJN.S46900 – ident: cit0115 doi: 10.1016/j.jcis.2016.07.020 – ident: cit0016 doi: 10.1080/21691401.2018.1559176 – ident: cit0062 doi: 10.1016/j.drudis.2020.06.027 – ident: cit0080 doi: 10.1166/jbn.2007.015 – ident: cit0063 doi: 10.1200/JCO.2007.15.0375 – ident: cit0081 doi: 10.1016/j.ijpharm.2010.12.040 – ident: cit0011 doi: 10.1007/978-3-319-50688-3_21 – ident: cit0059 doi: 10.1080/21691401.2019.1645152 – ident: cit0028 doi: 10.3389/fphar.2020.00898 – ident: cit0121 doi: 10.1016/j.jddst.2019.101316 – ident: cit0002 doi: 10.3390/nano10020183 – ident: cit0052 doi: 10.1186/1477-3155-11-1 – ident: cit0074 doi: 10.2174/1381612826666200318170716 – ident: cit0122 doi: 10.1016/j.jddst.2020.101502 – ident: cit0051 doi: 10.1016/j.biomaterials.2013.03.061 – ident: cit0100 doi: 10.1016/j.ejps.2017.03.025 – ident: cit0125 doi: 10.1016/j.biomaterials.2013.01.063 – ident: cit0103 doi: 10.1186/s12951-014-0037-5 – ident: cit0146 – ident: cit0046 doi: 10.2147/IJN.S30320 – ident: cit0021 doi: 10.1517/17425240902939143 – ident: cit0027 doi: 10.1016/j.biomaterials.2015.08.048 – ident: cit0135 doi: 10.1158/0008-5472.CAN-15-1558 – ident: cit0030 doi: 10.1016/j.actbio.2018.03.057 – ident: cit0105 doi: 10.1016/j.biomaterials.2013.05.018 – ident: cit0038 doi: 10.1080/10717544.2019.1642420 – ident: cit0076 doi: 10.2217/17435889.3.1.1 – ident: cit0078 doi: 10.1289/ehp.84553 – ident: cit0001 doi: 10.1016/j.jconrel.2018.12.002 – ident: cit0006 doi: 10.1517/17425240802652309 – ident: cit0085 doi: 10.1080/08958370601051677 – ident: cit0029 doi: 10.2147/IJN.S121881 – ident: cit0083 doi: 10.29245/2689-999X/2019/2.1148 |
| SSID | ssj0036701 |
| Score | 2.4018955 |
| SecondaryResourceType | review_article |
| Snippet | Nonsmall cell lung cancer (NSCLC) accounts for 80-85% of the cases of lung cancer. The conventional therapeutic effective dosage forms used to treat NSCLC are... |
| SourceID | proquest pubmed crossref informaworld |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 103 |
| SubjectTerms | animal studies cell line studies clinical trials gene delivery Nanocarriers NSCLC |
| Title | Targeted drug therapy in nonsmall cell lung cancer: clinical significance and possible solutions-part II (role of nanocarriers) |
| URI | https://www.tandfonline.com/doi/abs/10.1080/17425247.2021.1832989 https://www.ncbi.nlm.nih.gov/pubmed/33017541 https://www.proquest.com/docview/2448846106 |
| Volume | 18 |
| WOSCitedRecordID | wos000577292400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAWR databaseName: Taylor and Francis Online Journals customDbUrl: eissn: 1744-7593 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0036701 issn: 1742-5247 databaseCode: TFW dateStart: 20041101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NT9swFLcG2mEX2AaDMobepAkxibA6cRyX2zStGhfUQ9F6i_zxMiFlaZW0SD3tX59fnJRxQBzYMZGcxPbvfTnv_R5jn7SxNnFORdR6MRJ8aCITSxcZdI746LzODM0msutrNZuNJl02YdOlVVIMXQSiiFZXk3Br0_QZcV-8Ex2nsch8dBfzC8LkSFEJnzf91MNgOv7Z62JiJ-OhJJJCLpH1NTyPPeWBdXrAXfq4B9paovHuf5jDa7bTuaHwNeDmDXuB1Vt2Ogk81utzmN6XZTXncAqTe4br9R77M23zx9GBq1e_INRwreG2gsqD-LcuS6AfAlB6TQKWcFVfQl-DCZQyQglKdB_8BGAxJ8EsETZyEC08ouHqCs4o-xHmBVS68la3pv56zed9djP-Pv32I-o6OUQ2kXIZSYPC-kAyVbGQDlMUPq6LtdWGG8q9ccOh866Hi7nlqUPhNOrM8YLrAjFNs-Qd2_YTwEMGaRvNIw5lwYVRRkkUhTZSOJUZo_SAiX4Hc9vRnFO3jTLnHRtqv_Q5LX3eLf2AXWyGLQLPx1MDRv_CI1-2ByxF6IaSJ0-M_dhjKffSTDuiK5yvmtw7W0oRBb4csIMAss3nJF4XZ6ngR89483v2ii7bM6T4mG0v6xV-YC_t3fK2qU_YVjZTJ60E_QVVDBaX |
| linkProvider | Taylor & Francis |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Nb9MwFLdgILEL34zCgIeEJpCWrU5sx90NIapVjGqHIHaz_BU0KUurtEXqiX8dvzjptsO0A1wTOYnt3_ty3vs9Qj5oY23mnEyw9WLC6NAkJhUuMd455KMLOjM2m8inU3l2NrpaC4NplRhDl5EootXVKNx4GN2nxB0GLzrlKctDeJfSAwTlSI7ukns82FpEeTH-2Wtj5CejsSgSgy6W91U8Nz3mmn26xl56sw_a2qLxo_8xi8fkYeeJwucInSfkjq-fkr3TSGW93ofisjJrsQ97cHpJcr1-Rv4UbQq5d-Ca1S-IZVxrOK-hDji-0FUF-E8AqqBMwCK0miPoyzABs0YwRwmvQ5gBzGcom5WHjSgk8wBqmEzgIyZAwqyEWtfB8DbYYm_x6Tn5Mf5afDlOumYOic2EWCbCeGZDLMllyoTz3LMQ2qXaakMNpt-44dAF78Ol1FLuPHPa69zRkurSe87z7AXZChPwLwnwNqD3fihKyow0UnhWaiOYk7kxUg8I67dQ2Y7pHBtuVIp2hKj90itcetUt_YAcbIbNI9XHbQNGV_Ghlu0ZSxkboqjslrHvezCpINC4I7r2s9VCBX9LSmTBFwOyE1G2-ZwsqOOcM_rqH978jjw4Lr6fqJPJ9Ntrso232iOldJdsLZuVf0Pu29_L80XzthWkv1-WGdo |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9NAEF2VFqFeoHy0pKUwSKgCqW6z9nq96a1qiYhAUQ5B9LbaL1eVjBPZCVJO_HV2vHZKD1UPcLW1tnf9ZnbGfvOGkA9KG5NYKyJsvRgx2teRjrmNtLMW9ei8zwzNJrLxWFxdDSYtm7BuaZWYQ-dBKKLx1Wjcc5t3jLhTH0THacwyn93F9AQxORCDR2TLh84c86_p8EfnjFGejIaaSMy5WNYV8dx3mTvb0x3x0vtD0GYrGj77D5PYIU_bOBTOA3Cekw1XviBHkyBkvTqG6W1dVn0MRzC5lbhevSS_pw2B3Fmw1fIaQhHXCm5KKD2Kf6qiAPwjAIV3JWAQWNUZdEWYgJwRZCjhcfATgPkMLbNwsDaEaO4hDaMRfET6I8xyKFXpt90KG-zVn16R78PP04svUdvKITIJ54uIa8eMzyRTETNuXeqYT-xiZZSmGsk3tt-3PvawMTU0tY5Z5VRmaU5V7lyaZsku2fQTcK8JpE0671yf55RpoQV3LFeaMysyrYXqEda9QWlanXNst1FI2sqhdksvcellu_Q9crIeNg9CHw8NGPwND7lovrDkoR2KTB4Y-77DkvTmjG9ElW62rKWPtoRADXzeI3sBZOvHSbwzzlJG9__hzu_Ik8nlUH4bjb8ekG0803xPit-QzUW1dIfksfm1uKmrt40Z_QHyShiL |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeted+drug+therapy+in+nonsmall+cell+lung+cancer%3A+clinical+significance+and+possible+solutions-part+II+%28role+of+nanocarriers%29&rft.jtitle=Expert+opinion+on+drug+delivery&rft.au=Yadav%2C+Khushwant+S.&rft.au=Upadhya%2C+Archana&rft.au=Misra%2C+Ambikanandan&rft.date=2021-01-02&rft.issn=1742-5247&rft.eissn=1744-7593&rft.volume=18&rft.issue=1&rft.spage=103&rft.epage=118&rft_id=info:doi/10.1080%2F17425247.2021.1832989&rft.externalDBID=n%2Fa&rft.externalDocID=10_1080_17425247_2021_1832989 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1742-5247&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1742-5247&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1742-5247&client=summon |